No Data
Yiming Pharmaceutical: Report for the third quarter of 2024
tibet aim pharm. inc. (002826.SZ) released its performance for the first three quarters, with a net income of 41.8194 million yuan, a year-on-year increase of 75.06%.
tibet aim pharm. inc. (002826.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Tibet Aim Pharm. Inc. (002826.SZ): No planting industry of Tibetan medicinal materials at present.
Tibet AIM Pharm. Inc. (002826.SZ) stated on the investor interaction platform on September 12th that the company currently has no business in the planting industry of Tibetan medicinal materials.
Tibet AIM Pharm. Inc. (002826.SZ): The second-level wholly-owned subsidiary plans to conduct targeted capital reduction for Cayman Biai.
Grain 9th, tibet aim pharm. inc. (002826.SZ) announced that its wholly-owned subsidiary, TAPI Healthcare Inc. (referred to as "TAPI"), plans to make a targeted reduction in the share capital of its shareholding company, Pier 88 Health Limited (referred to as "Cayman Pied Love"). The two parties intend to sign a "Share Repurchase Agreement", which stipulates that TAPI plans to sell all of its shares, with a total repurchase price of $6,491,178.08.
Tibet Aim Pharm. Inc. (002826.SZ): The company did not conduct share repurchases in August.
On September 2, Gelonhui reported that Tibet Aim Pharm. Inc. (002826.SZ) announced that the company did not repurchase any shares in August 2024. As of August 31, 2024, the company has repurchased a total of 7,203,800 shares through the stock repurchase special securities account in a centralized auction trading method, accounting for 3.7780% of the company's current total share capital. The highest fill price was 8.96 yuan/share, and the lowest fill price was 5.84 yuan/share. The total repurchase amount was 50,000,572.63 yuan (excluding transaction costs).
Tibet Aim Pharm. Inc.: Summary of Half-Year Report in 2024.
No Data
No Data